Researchers developed an in-hospital mortality prognostic model using 5 independent predictor covariates to calculate a severity-of-illness score for patients with SJS/TEN.
Researchers retrospectively evaluated patients who underwent treatment with cytotoxic chemotherapy and developed either persistent chemotherapy-induced alopecia or endocrine therapy-induced alopecia.
Two phase 1 studies assessed the safety, tolerability, and pharmacokinetics of tezepelumab with evidence of efficacy in asthma and potential therapeutic benefit in atopic dermatitis.
Researchers formulated an optimal standardized total body skin examinations taking into account efficiency, missed body parts, and movements.
Phase 2 study results showed that mirikizumab-treated patients had significantly higher efficacy compared to placebo, with comparable safety profiles.
Review revealed that activated, leukocyte and platelet-rich plasma in combination with fractional ablative laser treatment improved the appearance of acne scars.
Long-term control of eczema requires the involvement of multiple stakeholder groups.
Secukimumab may be an effective treatment option for patients with moderate to severe palmoplantar pustular psoriasis.
Data from 4 phase 3 trials suggest that all anatomic regions are equally responsive to dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
Acne relapses were significantly associated with impaired quality of life and productivity loss.
